SymbolRGEN
NameREPLIGEN CORP
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address41 SEYON STREET, WALTHAM, MA 02453
Telephone7814499560
Fax
Email
Websitehttps://www.repligen.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000730272
Description

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The companys customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the companys revenue is generated in North America.

Additional info from NASDAQ:
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The companys customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the companys revenue is generated in North America.

2026-06-25 17:55

📋 Garland Jason K (Officer) plans to sell 733 shares of REPLIGEN CORP (at $145.00 each, total $106K) Filed: Jun 25, 2026 | ID: 004882

Read more
2026-05-22 11:30

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

Read more
2026-05-20 11:30

Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report

Read more
2026-05-18 20:05

Konstantinov Konstantin 🟢 acquired 3.2K shares (1 derivative) of REPLIGEN CORP (RGEN) at $103.38 Transaction Date: May 14, 2026 | Filing ID: 228897

Read more
2026-05-18 20:05

DAWES KAREN A 🟢 acquired 3.2K shares (1 derivative) of REPLIGEN CORP (RGEN) at $103.38 Transaction Date: May 14, 2026 | Filing ID: 228884

Read more
2026-05-18 20:05

MUIR GLENN P 🟢 acquired 3.2K shares (1 derivative) of REPLIGEN CORP (RGEN) at $103.38 Transaction Date: May 14, 2026 | Filing ID: 228891

Read more
2026-05-18 20:05

BARTHELEMY NICOLAS 🟢 acquired 3.2K shares (1 derivative) of REPLIGEN CORP (RGEN) at $103.38 Transaction Date: May 14, 2026 | Filing ID: 228883

Read more
2026-05-15 12:09

(99% Neutral) REPLIGEN CORP (RGEN) Announces Regulatory Update

Read more
2026-05-08 18:48

MUIR GLENN P 🟢 acquired 4.9K shares (1 derivative) of REPLIGEN CORP (RGEN) at $38.76 Transaction Date: May 07, 2026 | Filing ID: 214293

Read more
2026-05-08 18:39

Douglass Brian Robb 🔴 sold 334 shares of REPLIGEN CORP (RGEN) at $126.43 Transaction Date: May 07, 2026 | Filing ID: 214265

Read more